The FDA has escalated the recall of specific Abbott FreeStyle Libre 3 and 3 Plus CGMs to Class I, the highest level of ...
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Abbott (NYSE:ABT) is facing an FDA warning letter alleging quality system regulation violations related to FreeStyle Libre CGM production.
The Food and Drug Administration (FDA) has now identified the previous recall of certain FreeStyle Libre glucose monitor ...
Abbott Diabetes Care has recalled some of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors for people with diabetes.
Check Your CGM: Recalled FreeStyle Libre 3 Sensors Associated With 7 Deaths ...
The FDA has updated some information about the December recall of certain Abbott FreeStyle Libre 3 and 3 Plus glucose sensors ...
Abbott Laboratories is cited for four key alleged violations related to the production of its Freestyle Libre continuous ...
Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor (CGM) franchise, FreeStyle Libre. | Abbott has been hit with a slew of ...
Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results